ORGANIC
LETTERS
2013
Vol. 15, No. 7
1464–1467
Synthesis of the C‑18ÀC-34 Fragment
of Amphidinolides C, C2, and C3
J. Stephen Clark,* Guang Yang, and Andrew P. Osnowski
WestCHEM, School of Chemistry, Joseph Black Building, University of Glasgow,
University Avenue, Glasgow G12 8QQ, United Kingdom
Received February 21, 2013
ABSTRACT
The C-18ÀC-34 fragment of amphidinolides C, C2, and C3 and the C-18ÀC-29 fragment of amphidinolide F have been constructed from a trans-2,5-
disubstituted dihydrofuran. This key intermediate was prepared from a dihydrofuranone formed by diastereoselective rearrangement of a free or
metal-bound oxonium ylide generated from a metal carbenoid. The side chains found in amphidinolides C and F were introduced using
Sonogashira coupling reactions.
The amphidinolides are macrolide natural products
extracted from symbiotic dinoflagellates of the genus
Amphidinium cultivated from the Okinawan flatworms of
the Amphiscolops species. Several members of this diverse
group of macrolides exhibit potent cytotoxicity and pos-
sess other biological activities, but in most cases the
substantial quantities of material required in order to fully
establish their therapeutic potential are not available.1
Amphidinolide C2 (1) and the closely related congeners
amphidinolides C23 (2), C34 (3), and F5 (4) are particularly
attractive targets for total synthesis because of their power-
ful in vitro activities and the synthetic challenges that
their complex molecular architectures present (Figure 1).
Several groups have reported syntheses of fragments of
these natural products,2bÀd,6 but only very recently has a
total synthesis of one member of the family, amphidinolide
F (4), been published.7
Amphidinolide C was isolated by Kobayashi et al. in
1988 and was found to possess cytotoxic activity against
both murine lymphoma and epidermoid carcinoma KB
cell lines.2 Subsequently, the absolute and relative config-
urations of this and the other natural products in the series
were established and their bioactivities were determined,
(1) (a) Kobayashi, J.; Ishibashi, M. Chem. Rev. 1993, 93, 1753.
(b) Kobayashi, J.; Tsuda, M. Nat. Prod. Rep. 2004, 21, 77. (c) Kobayashi,
J.; Kubota, T. J. Nat. Prod. 2007, 70, 451. (d) Kobayashi, J. J. Antibiot.
2008, 61, 271.
€
(2) (a) Kobayashi, J.; Ishibashi, M.; Walchli, M. R.; Nakamura, H.;
Hirata, Y.; Sasaki, T.; Ohizumi, Y. J. Am. Chem. Soc. 1988, 110, 490.
(b) Ishiyama, H.; Ishibashi, M.; Kobayashi, J. Chem. Pharm. Bull. 1996,
44, 1819. (c) Kubota, T.; Tsuda, M.; Kobayashi, J. Org. Lett. 2001, 3,
1363. (d) Kubota, T.; Tsuda, M.; Kobayashi, J. Tetrahedron 2003, 59,
1613.
(3) Kubota, T.; Sakuma, Y.; Tsuda, M.; Kobayashi, J. Mar. Drugs
2004, 2, 83.
(4) Kubota, T.; Suzuki, A.; Yamada, M.; Baba, S.; Kobayashi, J.
(6) (a) Shotwell, J. B.; Roush, W. R. Org. Lett. 2004, 6, 3865.
(b) Mohapatra, D. K.; Rahaman, H.; Chorghade, M. S.; Gurjar,
M. K. Synlett 2007, 4, 567. (c) Bates, R. H.; Shotwell, J. B.; Roush,
W. R. Org. Lett. 2008, 10, 4343. (d) Armstrong, A.; Pyrkotis, C.
Tetrahedron Lett. 2009, 50, 3325. (e) Mahapatra, S.; Carter, R. G.
Org. Biomol. Chem. 2009, 7, 4582. (f) Paudyal, M. P.; Rath, N. P.;
Spilling, C. D. Org. Lett. 2010, 12, 2954. (g) Ferrie, L.; Figadere, B. Org.
Lett. 2010, 12, 4976. (h) Roy, S.; Spilling, C. D. Org. Lett. 2010, 12, 5326.
(i) Morra, N. A.; Pagenkopf, B. L. Org. Lett. 2011, 13, 572.
(7) Mahapatra, S.; Carter, R. G. Angew. Chem., Int. Ed. 2012, 51,
7948.
ꢀ
ꢁ
Heterocycles 2010, 82, 333.
(5) Kobayashi, J.; Tsuda, M.; Ishibashi, M.; Shigemori, H.; Yamasu,
T.; Hirota, H.; Sasaki, T. J. Antibiot. 1991, 44, 1259.
r
10.1021/ol400482j
Published on Web 03/25/2013
2013 American Chemical Society